Condition: Lupus Nephritis · Sponsor: Autolus Limited
The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).
This description comes directly from the study's public registry record.
Autolus Ltd · +44 (0)203 911 4385 · clinicaltrials@autolus.com
Always discuss trial participation with your own doctor first.
| State University of New York Upstate Medical Center (SUNY) | Syracuse, New York, United States | Recruiting |
| Texas Transplant Institute | San Antonio, Texas, United States | Recruiting |
| University General Hospital ATTIKON | Athens, Greece | Recruiting |
| University General Hospital of Patras | Pátrai, Greece | Recruiting |
| Queen Elizabeth Hospital Birmingham | Birmingham, United Kingdom | Recruiting |
| Bristol Haematology and Oncology Centre | Bristol, United Kingdom | Recruiting |
| Addenbrooke's Hospital | Cambridge, United Kingdom | Recruiting |
| Western General Hospital Edinburgh | Edinburgh, United Kingdom | Recruiting |
| Queen Elizabeth University Hospital | Glasgow, United Kingdom | Recruiting |
| University College Hospital | London, United Kingdom | Recruiting |
| Great Ormond Street Hospital | London, United Kingdom | Recruiting |
| Manchester Royal Infirmary | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07053800